Stephan R Vavricka
Probiotika in der Gastroenterologie
Kueres-Wiese A, Vavricka S, Baumann P. Probiotika in der Gastroenterologie. Swiss Med Forum 2023; 2023:1482-1487.
Dec 6, 2023Probiotika in der Gastroenterologie
Dec 6, 2023Swiss Med Forum 2023; 2023:1482-1487
Kueres-Wiese Alexander, Vavricka Stephan R, Baumann Philippe
Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland.
Perrig K, Krupka N, Jordi S, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka S, Juillerat P, Burri E, Zimmermann D, Maillard M, Sulz M, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therap Adv Gastroenterol 2022; 15:17562848221074188.
Feb 9, 2022Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland.
Feb 9, 2022Therap Adv Gastroenterol 2022; 15:17562848221074188
Perrig Kathrin, Krupka Niklas, Jordi Sebastian Bruno Ulrich, Rossel Jean-Benoit, Biedermann Luc, Greuter Thomas, Schreiner Philipp, Vavricka Stephan R, Juillerat Pascal, Burri Emanuel, Zimmermann Dorothee, Maillard Michel H, Sulz Michael Christian, Brand Stephan, Rogler Gerhard, Misselwitz Benjamin
Fatigue in inflammatory bowel disease and its impact on daily activities
Schreiner P, Misselwitz B, von Känel R, Rogler G, Juillerat P, Pittet V, Vavricka S, Scharl M, Greuter T, Baumann C, Valko P, Biedermann L, Rossel J, Swiss IBD Cohort Study Group. Fatigue in inflammatory bowel disease and its impact on daily activities. Aliment Pharmacol Ther 2020; 53:138-149.
Nov 7, 2020Fatigue in inflammatory bowel disease and its impact on daily activities
Nov 7, 2020Aliment Pharmacol Ther 2020; 53:138-149
Schreiner Philipp, Misselwitz Benjamin, von Känel Roland, Rogler Gerhard, Juillerat Pascal, Pittet Valérie, Vavricka Stephan R, Scharl Michael, Greuter Thomas, Baumann Christian R, Valko Philipp O, Biedermann Luc, Rossel Jean-Benoit, Swiss IBD Cohort Study Group
Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know
Schreiner P, Rogler G, Juillerat P, Vavricka S, Vulliemoz M, Restellini S, Schoepfer A, Michetti P, Brand S, Maillard M, Fehr J, Mueller N, Biedermann L. Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. J Crohns Colitis 2020
Jun 27, 2020Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know
Jun 27, 2020J Crohns Colitis 2020
Schreiner Philipp, Rogler Gerhard, Juillerat Pascal, Vavricka Stephan R, Vulliemoz Marianne, Restellini Sophie, Schoepfer Alain, Michetti Pierre, Brand Stephan, Maillard Michel H, Fehr Jan, Mueller Nicolas J, Biedermann Luc
Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis
Greuter T, Vavricka S, Biedermann L, Pilz J, Borovicka J, Seibold F, Sauter B, Rogler G. Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. Dig Dis 2017
Dec 5, 2017Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis
Dec 5, 2017Dig Dis 2017
Greuter Thomas, Vavricka Stephan R, Biedermann Luc, Pilz Julia, Borovicka Jan, Seibold Frank, Sauter Bernhard, Rogler Gerhard
Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey
Vavricka S, Biedermann L, Michetti P, Straumann A, Misselwitz B, Scharl M, Manser C, Greuter T, Zeitz J, Frei P, Borovicka J, Seibold F, Schoepfer A, Rogler G, Spasojevic M. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey. Dig Dis 2017; 35:423-432.
Jun 9, 2017Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey
Jun 9, 2017Dig Dis 2017; 35:423-432
Vavricka Stephan R, Biedermann Luc, Michetti Pierre, Straumann Alex, Misselwitz Benjamin, Scharl Michael, Manser Christine, Greuter Thomas, Zeitz Jonas, Frei Pascal, Borovicka Jan, Seibold Frank, Schoepfer Alain M, Rogler Gerhard, Spasojevic Milos
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study
Vavricka S, Misselwitz B, Scharl M, Heinrich H, Manser C, Safroneeva E, Raja Ali R, Rogler G, Schoepfer A, Greuter T, Zeitz J, Biedermann L, Juillerat P, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. Inflamm Bowel Dis 2017
Apr 27, 2017Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study
Apr 27, 2017Inflamm Bowel Dis 2017
Vavricka Stephan R, Misselwitz Benjamin, Scharl Michael, Heinrich Henriette, Manser Christine N, Safroneeva Ekaterina, Raja Ali Raja Affendi, Rogler Gerhard, Schoepfer Alain M, Greuter Thomas, Zeitz Jonas, Biedermann Luc, Juillerat Pascal, Gubler Martin, Gantenbein Claudine, Spoerri Muriel, Froehlich Florian, Seibold Frank, Protic Marijana, Michetti Pierre, Straumann Alex, Fournier Nicolas
Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort
Zeitz J, Rogler G, Fried M, Sulz M, Vavricka S, Scharl S, Misselwitz B, Frei P, Biedermann L, Labenz C, Fournier N, Scharl M. Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Intest Dis 2017; 1:172-181.
Feb 25, 2017Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort
Feb 25, 2017Inflamm Intest Dis 2017; 1:172-181
Zeitz Jonas, Rogler Gerhard, Fried Michael, Sulz Michael, Vavricka Stephan R, Scharl Sylvie, Misselwitz Benjamin, Frei Pascal, Biedermann Luc, Labenz Christian, Fournier Nicolas, Scharl Michael
Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience
Bontà J, Rogler G, Fried M, Scharl S, Vavricka S, Sulz M, Biedermann L, Frei P, Zeitz J, Scharl M. Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience. Eur J Gastroenterol Hepatol 2016; 28:1329-34.
Nov 1, 2016Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience
Nov 1, 2016Eur J Gastroenterol Hepatol 2016; 28:1329-34
Bontà Jonas, Rogler Gerhard, Fried Michael, Scharl Sylvie, Vavricka Stephan R, Sulz Michael, Biedermann Luc, Frei Pascal, Zeitz Jonas, Scharl Michael
Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort
Spalinger M, Scharl M, Rogler G, Fried M, Vavricka S, Scharl S, Frei P, Sulz M, Rossel J, Biedermann L, Zeitz J. Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort. PloS one 2016; 11:e0160215.
Jul 28, 2016Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort
Jul 28, 2016PloS one 2016; 11:e0160215
Spalinger Marianne R, Scharl Michael, Rogler Gerhard, Fried Michael, Vavricka Stephan R, Scharl Sylvie, Frei Pascal, Sulz Michael, Rossel Jean-Benoit, Biedermann Luc, Zeitz Jonas
Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience
Madanchi M, Rogler G, Vavricka S, Frei P, Biedermann L, Sulz M, Scharl S, Samaras P, Barthel C, Zeitz J, Scharl M. Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience. Digestion 2016; 94:1-8.
Jun 18, 2016Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience
Jun 18, 2016Digestion 2016; 94:1-8
Madanchi Mehdi, Rogler Gerhard, Vavricka Stephan R, Frei Pascal, Biedermann Luc, Sulz Michael, Scharl Sylvie, Samaras Panagiotis, Barthel Christiane, Zeitz Jonas, Scharl Michael
The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease
Vögelin M, Rogler G, Fried M, Sulz M, Zeitz J, Scharl S, Vavricka S, Frei P, Biedermann L, Scharl M. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. PloS one 2016; 11:e0155218.
May 23, 2016The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease
May 23, 2016PloS one 2016; 11:e0155218
Vögelin Marius, Rogler Gerhard, Fried Michael, Sulz Michael, Zeitz Jonas, Scharl Sylvie, Vavricka Stephan R, Frei Pascal, Biedermann Luc, Scharl Michael
The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort
Spalinger M, Scharl M, Rogler G, Fried M, Vavricka S, Scharl S, Frei P, Sulz M, Rossel J, Zeitz J, Biedermann L, Voegelin M. The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort. Digestion 2016; 93:182-92.
Feb 27, 2016The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort
Feb 27, 2016Digestion 2016; 93:182-92
Spalinger Marianne R, Scharl Michael, Rogler Gerhard, Fried Michael, Vavricka Stephan R, Scharl Sylvie, Frei Pascal, Sulz Michael, Rossel Jean-Benoit, Zeitz Jonas, Biedermann Luc, Voegelin Marius
Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists
Vavricka S, Rogler G, Safroneeva E, Peter S, Beglinger C, Biedermann L, Manz M, Rechner R, Degen L, Sulz M, Schoepfer A. Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists. Endoscopy 2016
Jan 25, 2016Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists
Jan 25, 2016Endoscopy 2016
Vavricka Stephan R, Rogler Gerhard, Safroneeva Ekaterina, Peter Shajan, Beglinger Christoph, Biedermann Luc, Manz Michael, Rechner Roman, Degen Lukas, Sulz Michael, Schoepfer Alain M
Risk factors for complications in patients with ulcerative colitis
Manser C, Borovicka J, Seibold F, Vavricka S, Lakatos P, Fried M, Rogler G. Risk factors for complications in patients with ulcerative colitis. United European Gastroenterol J 2016; 4:281-7.
Jan 19, 2016Risk factors for complications in patients with ulcerative colitis
Jan 19, 2016United European Gastroenterol J 2016; 4:281-7
Manser Christine N, Borovicka Jan, Seibold Frank, Vavricka Stephan R, Lakatos Peter L, Fried Michael, Rogler Gerhard
Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey
Barthel C, Rogler G, Wiegand N, Sulz M, Fried M, Vavricka S, Frei P, Scharl M, Scharl S, Wiegand S, Biedermann L. Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey. Nutr J 2015; 14:78.
Aug 12, 2015Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey
Aug 12, 2015Nutr J 2015; 14:78
Barthel Christiane, Rogler Gerhard, Wiegand Nico, Sulz Michael, Fried Michael, Vavricka Stephan R, Frei Pascal, Scharl Michael, Scharl Sylvie, Wiegand Sandra, Biedermann Luc
Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study
Sulz M, Sagmeister M, Meyenberger C, Vavricka S, von Känel R, Wurm J, Gothe R, Arvandi M, Siebert U, Swiss IBD Cohort Study Group. Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study. Eur J Gastroenterol Hepatol 2013; 25:790-7.
Jul 1, 2013Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study
Jul 1, 2013Eur J Gastroenterol Hepatol 2013; 25:790-7
Sulz Michael, Sagmeister Markus, Meyenberger Christa, Vavricka Stephan R, von Känel Roland, Wurm Johannes, Gothe Raffaella M, Arvandi Marjan, Siebert Uwe, Swiss IBD Cohort Study Group
Predictors of Temporary and Permanent Work Disability in Patients With Inflammatory Bowel Disease: Results of the Swiss Inflammatory Bowel Disease Cohort Study
Siebert U, Sagmeister M, Meyenberger C, Sulz M, Begré S, von Känel R, Vavricka S, Arvandi M, Gothe R, Wurm J, the Swiss IBD Cohort Study Group. Predictors of Temporary and Permanent Work Disability in Patients With Inflammatory Bowel Disease: Results of the Swiss Inflammatory Bowel Disease Cohort Study. Inflamm Bowel Dis 2013; 19:847-855.
Mar 1, 2013Predictors of Temporary and Permanent Work Disability in Patients With Inflammatory Bowel Disease: Results of the Swiss Inflammatory Bowel Disease Cohort Study
Mar 1, 2013Inflamm Bowel Dis 2013; 19:847-855
Siebert Uwe, Sagmeister Markus, Meyenberger Christa, Sulz Michael, Begré Stefan, von Känel Roland, Vavricka Stephan R, Arvandi Marjan, Gothe Raffaella Matteucci, Wurm Johannes, the Swiss IBD Cohort Study Group
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey
Vavricka S, Michetti P, Straumann A, Seibold F, Scharl M, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Bansky G, Schoepfer A, for the Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis 2010
Dec 22, 2010Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey
Dec 22, 2010Inflamm Bowel Dis 2010
Vavricka Stephan R, Michetti Pierre, Straumann Alex, Seibold Frank, Scharl Michael, Sauter Bernhard, de Saussure Philippe, Rogler Gerhard, Manz Michael, Geyer Martin, Felley Christian, Binek Janek, Bansky Georg, Schoepfer Alain M, for the Swiss IBDnet
Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey
Schoepfer A, Straumann A, Seibold F, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Vavricka S, Michetti P. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. Inflammatory bowel diseases 2009
Dec 10, 2009Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey
Dec 10, 2009Inflammatory bowel diseases 2009
Schoepfer Alain M, Straumann Alex, Seibold Frank, Sauter Bernhard, de Saussure Philippe, Rogler Gerhard, Manz Michael, Geyer Martin, Felley Christian, Binek Janek, Vavricka Stephan R, Michetti Pierre